← Back to Clinical Trials
Recruiting NCT05761093

NCT05761093 Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05761093
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Prostate Cancer
Study Type OBSERVATIONAL
Enrollment 306 participants
Start Date 2022-09-07
Primary Completion 2025-12-31

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 306 participants in total. It began in 2022-09-07 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study is to examine the preference weightings in term of risk/ benefit attributes of treatment in physician and prostate cancer patients from different stages of disease.

Eligibility Criteria

Inclusion Criteria: * aged 18 years or older, * diagnosis of metastatic prostate cancer within 5 years, * able to read and write, * accepting and signing the informed consent Exclusion Criteria: * if patients are unable to complete the survey by themselves due to physical or psychological reasons, * deemed ineligible by treating physicians if patients are unable to complete the survey by themselves due to physical or psychological reasons, * deemed ineligible by treating physicians

Contact & Investigator

Central Contact

Chi Fai NG, MD

✉ ngcf@surgery.cuhk.edu.hk

📞 35052625

Principal Investigator

Chi Fai NG, MD

PRINCIPAL INVESTIGATOR

Chinese University of Hong Kong

Frequently Asked Questions

Who can join the NCT05761093 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05761093 currently recruiting?

Yes, NCT05761093 is actively recruiting participants. Contact the research team at ngcf@surgery.cuhk.edu.hk for enrollment information.

Where is the NCT05761093 trial being conducted?

This trial is being conducted at Shatin, Hong Kong.

Who is sponsoring the NCT05761093 clinical trial?

NCT05761093 is sponsored by Chinese University of Hong Kong. The principal investigator is Chi Fai NG, MD at Chinese University of Hong Kong. The trial plans to enroll 306 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology